https://asthra-writer.ai Articles and analysis from the Asthra team on AI in regulated writing, provenance, citation graphs, and the regulatory landscape. en-us Mon, 07 Sep 2026 00:00:00 GMT https://asthra-writer.ai/blog/correct-numbers-wrong-population https://asthra-writer.ai/blog/correct-numbers-wrong-population Mon, 07 Sep 2026 00:00:00 GMT Our drafting agent used subgroup results to describe overall safety. Our automated evaluator missed it. What this taught us about checking the claim behind the numbers. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/bayesian-protocol-must-argue-for-its-prior https://asthra-writer.ai/blog/bayesian-protocol-must-argue-for-its-prior Tue, 01 Sep 2026 00:00:00 GMT FDA's January 2026 draft guidance on Bayesian methodology carries a documentation section that asks the protocol to justify the prior distribution, describe every external source that informed it, name the sources excluded and why, and account for evidence suggesting skepticism. The writing burden is provenance. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/drug-interactions-section-7-prose https://asthra-writer.ai/blog/drug-interactions-section-7-prose Tue, 01 Sep 2026 00:00:00 GMT FDA's draft guidance on drug interaction labeling tells applicants which phrasings to prefer, what order the sentences go in, when to use a table, and to write in the active voice. Two agency webinars on 23 September walk through it. It is one of the most explicit pieces of editorial direction FDA has published for a single label section. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/one-pacmp-six-regulators https://asthra-writer.ai/blog/one-pacmp-six-regulators Tue, 01 Sep 2026 00:00:00 GMT FDA, EMA, TGA, Health Canada, PMDA and Swissmedic assessed the same post-approval change management protocol at the same time, coordinated their questions, and reached aligned decisions within days of each other. The protocol covered several biological products across four therapy areas. The lesson for CMC writers is not faster review, but a document that has to survive six readings on the first pass. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/who-wrote-this-sentence-three-revision-origins https://asthra-writer.ai/blog/who-wrote-this-sentence-three-revision-origins Wed, 26 Aug 2026 00:00:00 GMT Most AI writing tools insert machine-generated text under the writer's name, which in data-integrity terms is a shared identity. The document record we designed for Asthra distinguishes three origins for every revision: the writer edited, the writer commanded the machine, or the machine acted in its own flow. The writer who requested a change is recorded as the commander, never as the author. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/ten-questions-one-meeting-package https://asthra-writer.ai/blog/ten-questions-one-meeting-package Mon, 24 Aug 2026 00:00:00 GMT FDA's final guidance on formal meetings sets out what a meeting package should contain, caps the questions at ten including subquestions, and describes a document built for a reviewer to navigate. It also sets out who writes the summary that becomes the official record. For anyone drafting the package, the specification is unusually explicit about the writing. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/tudriqev-objection-2021-approval-2026 https://asthra-writer.ai/blog/tudriqev-objection-2021-approval-2026 Mon, 17 Aug 2026 00:00:00 GMT At a Type B meeting in March 2021, FDA told Replimune that responses in injected lesions were problematic for an intratumoral therapy. Five years, two complete response letters and an advisory committee later, the product was approved on an analysis restricted to patients who had a lesion that was never injected. The objection never changed. The document that answered it did. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/capricor-replimune-adcomm-record https://asthra-writer.ai/blog/capricor-replimune-adcomm-record Thu, 13 Aug 2026 00:00:00 GMT On 29 and 30 July the same FDA advisory committee voted on two products and was asked a different question about each. Replimune was approved on 6 August after two prior rejections. Capricor's decision is due 22 August. A factual record of what was asked, what was voted, and what the approval rests on. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/cber-updated-sopp-8401-there-is-no-redline https://asthra-writer.ai/blog/cber-updated-sopp-8401-there-is-no-redline Wed, 05 Aug 2026 00:00:00 GMT SOPP 8401 governs what happens to an original BLA before the science gets its full review. Its effective date is now 29 July 2026. Sixteen of CBER's fifty-six published procedures carry a 2026 date in a year barely half over. There is no Federal Register notice, no docket, no comment period and no redline for any of them. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/fda-challenged-two-sponsors-efficacy-cases https://asthra-writer.ai/blog/fda-challenged-two-sponsors-efficacy-cases Wed, 05 Aug 2026 00:00:00 GMT On consecutive days in late July, FDA advisers voted 9-3 against Capricor's deramiocel and 10-3 that Replimune's IGNYTE results were evaluable and clinically meaningful. Both sponsors walked in behind an FDA briefing document that publicly challenged their efficacy case. The agency's document set the terms of both arguments. It decided neither. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/asthra-resolves-the-flags-it-raises https://asthra-writer.ai/blog/asthra-resolves-the-flags-it-raises Mon, 03 Aug 2026 00:00:00 GMT Asthra used to flag the gaps it couldn't fill and leave them for the writer. Now it fills them: you point it at the source documents, and every change comes back as a tracked revision in Word you accept or reject yourself. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/fda-showed-you-the-safety-lens-its-reviewers-use https://asthra-writer.ai/blog/fda-showed-you-the-safety-lens-its-reviewers-use Wed, 29 Jul 2026 00:00:00 GMT CDER posted two on-demand webinars in June with no announcement: one on the standard safety tables and figures guide, one on the 104 Office of New Drugs Custom Medical Queries used for safety signal detection. They aren't requirements. They are a description of what happens to your adverse event data after it arrives. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/five-sources-moved-in-five-weeks https://asthra-writer.ai/blog/five-sources-moved-in-five-weeks Wed, 29 Jul 2026 00:00:00 GMT A withdrawn guidance, an advisory committee whose charter lapsed, two retracted papers, a set of journal articles the agency has now disowned, and a rejection-letter programme that paused and restarted. Regulatory documents record what they depend on. They can't tell you what depends on them. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/fda-cmc-readiness-strategy-while-ending-the-pilot https://asthra-writer.ai/blog/fda-cmc-readiness-strategy-while-ending-the-pilot Mon, 27 Jul 2026 00:00:00 GMT On 23 July FDA published a strategy document naming CMC readiness as the thing that breaks on accelerated timelines. The same week it emerged that the pilot built for exactly that problem is winding down, undersubscribed, after three years. In the published rejection letters, 65% cite facility deficiencies and 51% cite CMC — against 26% for efficacy. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/document-was-never-the-source-of-truth https://asthra-writer.ai/blog/document-was-never-the-source-of-truth Thu, 23 Jul 2026 00:00:00 GMT Regulatory writing treats the Word file as the thing you trust — the artifact you edit, version, and pass around. It isn't. The document is a render of decisions, data, and provenance that live somewhere else, and once you take that seriously the whole tool changes shape. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/expedited-lane-is-now-the-default https://asthra-writer.ai/blog/expedited-lane-is-now-the-default Tue, 21 Jul 2026 00:00:00 GMT More than 70% of last year's new drugs took an expedited path, and most of this month's designations are Fast Track or Orphan. The compressed timeline lands on a part of the process nobody plans for — the drafting. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/fda-reversed-its-crl-pause https://asthra-writer.ai/blog/fda-reversed-its-crl-pause Wed, 15 Jul 2026 00:00:00 GMT The FDA paused public release of Complete Response Letters, then posted 14 new ones days later. The policy will keep swinging. Meanwhile there were 455 rejection letters already in the public database when I checked, and almost no one drafting submissions is reading them. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/solving-hallucinations-wont-make-an-ai-writing-tool-work https://asthra-writer.ai/blog/solving-hallucinations-wont-make-an-ai-writing-tool-work Mon, 13 Jul 2026 00:00:00 GMT Everyone asks whether the AI hallucinates, and assumes that if it doesn't, the product works. A regulated document is a big, coherent argument grounded in real data — and getting a tool to actually help write one takes more than accuracy. Perspective guru@asthra-writer.ai (Guruprasad Padmanabhan) https://asthra-writer.ai/blog/fda-pauses-crl-release-publishable-rejection-letters https://asthra-writer.ai/blog/fda-pauses-crl-release-publishable-rejection-letters Fri, 10 Jul 2026 00:00:00 GMT FDA has paused its proactive public release of Complete Response Letters while HHS works toward a formal disclosure rule. Whether CRLs remain confidential or become routinely publishable, the writing implication is immediate: sponsors should write submissions and CRL responses as if FDA's description of any deficiency could eventually be read by investors, competitors, journalists, litigators, and patient groups. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/cmc-module-3-a-data-problem-not-a-writing-one https://asthra-writer.ai/blog/cmc-module-3-a-data-problem-not-a-writing-one Fri, 03 Jul 2026 00:00:00 GMT A CMC / Module 3 dossier is mostly interlocking tables, and the same batch, impurity, and limit turn up across many of them. Keeping those appearances consistent, and traceable, is what makes Module 3 hard to automate — not the writing. Here's how we think about it. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/casgevy-53-day-cnpv-approval-review-window-no-ir-slack https://asthra-writer.ai/blog/casgevy-53-day-cnpv-approval-review-window-no-ir-slack Thu, 02 Jul 2026 00:00:00 GMT FDA approved expanded use of Vertex's Casgevy for patients aged 2 years and older with sickle cell disease or transfusion-dependent β-thalassemia, after a highly compressed review under the Commissioner's National Priority Voucher pilot. When the review window is measured in weeks, the dossier has to be review-ready at filing: internally consistent, cross-referenced, and pre-answered against foreseeable questions on pediatric extrapolation, conditioning risk, genome-editing safety, and long-term follow-up. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/china-trial-site-provenance-house-committee-probe https://asthra-writer.ai/blog/china-trial-site-provenance-house-committee-probe Thu, 02 Jul 2026 00:00:00 GMT A House China Select Committee inquiry into major drugmakers' clinical-trial activity in China has put trial-site geography under new scrutiny, including sites in Xinjiang and institutions linked to the Chinese military. For regulatory writing teams, the lesson is provenance: sponsors need to know where pivotal evidence came from, which claims depend on which sites or regions, and whether the benefit-risk case still stands if a regional data subset is challenged. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/pivotal-data-retraction-provenance-tavneos-nejm https://asthra-writer.ai/blog/pivotal-data-retraction-provenance-tavneos-nejm Thu, 02 Jul 2026 00:00:00 GMT NEJM retracted the pivotal ADVOCATE trial publication supporting Tavneos, while Nature Medicine retracted LungTIME-C01, a high-profile China-based trial on time-of-day immunochemotherapy in NSCLC. For regulatory writing teams, a retraction is a provenance event: the organisation must know quickly which claims, sections, documents, and arguments relied on the withdrawn source — and what remains supported without it. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/regulatory-review-fda-audit-inside-the-draft https://asthra-writer.ai/blog/regulatory-review-fda-audit-inside-the-draft Thu, 02 Jul 2026 00:00:00 GMT Asthra's Regulatory Review runs a section-by-section FDA/ICH audit right inside the document — grounded in curated ICH E3 expectations and real approved-product labeling from openFDA — and writes specific, actionable regulator flags inline where the writer works. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/sarepta-full-approval-after-confirmatory-trial-fails https://asthra-writer.ai/blog/sarepta-full-approval-after-confirmatory-trial-fails Thu, 02 Jul 2026 00:00:00 GMT Sarepta's ESSENCE confirmatory study for AMONDYS 45 and VYONDYS 53 did not meet statistical significance on its primary endpoint, but FDA has accepted sNDAs seeking conversion from accelerated to traditional approval, with a February 28, 2027 target action date. This is one of the hardest regulatory-writing cases: the submission has to acknowledge the failed confirmatory trial, reconcile the original dystrophin-surrogate rationale, and make a totality-of-evidence case without pretending the miss does not matter. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/abbvie-apogee-clinical-asset-in-flight-handoff https://asthra-writer.ai/blog/abbvie-apogee-clinical-asset-in-flight-handoff Wed, 24 Jun 2026 00:00:00 GMT AbbVie is acquiring Apogee Therapeutics for $10.9B, centered on zumilokibart / APG777, a half-life-extended anti-IL-13 antibody with Phase 2 atopic dermatitis data and broader potential in asthma and EoE. The regulatory-writing problem is not ordinary bolt-on cadence. It is a living-dossier handoff: open IND history, IB revisions, active trials, safety updates, and agency correspondence must move into AbbVie's system without losing continuity. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/operation-trialblazer-phase-appropriate-requirements-writing-organisation https://asthra-writer.ai/blog/operation-trialblazer-phase-appropriate-requirements-writing-organisation Wed, 24 Jun 2026 00:00:00 GMT FDA's Operation TrialBlazer aims to accelerate drug development from the pre-IND / IND transition through late-stage trials, with a Phase 1 IND Navigator, updated Phase 1 CMC resources, dose-selection guidance, master-protocol updates, and an explicit focus on phase-appropriate requirements. For regulatory writing teams, the implication is direct: every section now has to be scoped to the phase deliberately, with clear deferral language and reviewer-visible rationale. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/regenxbio-hunter-resubmission-fda-rare-disease-aboutface https://asthra-writer.ai/blog/regenxbio-hunter-resubmission-fda-rare-disease-aboutface Wed, 24 Jun 2026 00:00:00 GMT Regenxbio plans to resubmit NAVSUNLI / RGX-121 for Hunter syndrome without enrolling additional patients or running a new study, after FDA indicated the existing data could support accelerated approval. Coming days after FDA reopened uniQure's AMT-130 path, the move signals a more flexible rare-disease posture. The resubmission dossier now has to reconcile the prior CRL, make the existing evidence load-bearing, and carry a credible confirmatory plan. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/subgroup-failure-label-writing-pfizer-exelixis https://asthra-writer.ai/blog/subgroup-failure-label-writing-pfizer-exelixis Wed, 24 Jun 2026 00:00:00 GMT Pfizer's sigvotatug vedotin failed a late-stage lung cancer trial outright. Exelixis faces a harder writing problem: zanzalintinib plus atezolizumab met the OS endpoint in the ITT colorectal cancer population, but missed in the non-liver metastases subgroup while FDA reviews the NDA. Mixed-efficacy results are where benefit-risk, subgroup interpretation, and label scope have to be written with unusual discipline. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/the-safety-analysis-moved-to-itt https://asthra-writer.ai/blog/the-safety-analysis-moved-to-itt Mon, 22 Jun 2026 00:00:00 GMT A late change to the safety analysis population recomputes every adverse-event table, exposure summary, and benefit-risk paragraph in a CSR. Here's what that costs by hand — and what it costs with an agent that re-grounds every number in the source. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/fda-1000-ai-submissions-regulatory-writing-architecture https://asthra-writer.ai/blog/fda-1000-ai-submissions-regulatory-writing-architecture Thu, 18 Jun 2026 00:00:00 GMT At DIA, FDA officials said CDER and CBER have received more than 1,000 submissions incorporating AI elements. FDA is also advancing drug-repurposing work using real-world evidence, while industry is asking for more clarity on AI in manufacturing. None of this directly names regulatory writing. But all of it creates new writing surfaces: context of use, model credibility, RWE integration, and Module 3 descriptions of AI-supported quality systems. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/grace-science-cmc-gate-writing-under-rare-disease-runway-pressure https://asthra-writer.ai/blog/grace-science-cmc-gate-writing-under-rare-disease-runway-pressure Thu, 18 Jun 2026 00:00:00 GMT Grace Science is developing GS-100, an AAV9 gene replacement therapy for NGLY1 deficiency, and says FDA's plausible-mechanism framework has not resolved an unresolved manufacturing-data issue. The company is running short on capital and is seeking a path forward. For the writing organisation, the hard problem is CMC under runway pressure: making the existing manufacturing evidence, residual-risk argument, and post-approval commitment plan as clear and defensible as possible without pretending writing can replace missing data. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/jazz-abcellera-tce-pact-pre-ind-writing-before-modality-locked https://asthra-writer.ai/blog/jazz-abcellera-tce-pact-pre-ind-writing-before-modality-locked Thu, 18 Jun 2026 00:00:00 GMT Jazz Pharmaceuticals and AbCellera announced a staged T-cell engager collaboration that could reach multibillion-dollar value if multiple programs advance and milestones are met. The programs are preclinical, but the writing work starts now — construct vocabulary, mechanism description, safety logic, dose-finding rationale, CMC language, and partner-to-sponsor handoff conventions will shape every future regulatory document. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/lilly-4e-bolt-on-integration-writing-organisation-function https://asthra-writer.ai/blog/lilly-4e-bolt-on-integration-writing-organisation-function Thu, 18 Jun 2026 00:00:00 GMT Eli Lilly's acquisition of 4E Therapeutics adds another non-opioid pain platform to its 2026 deal run. Against a broader biopharma backdrop of larger partnerships and rising China-sourced licensing, the durable problem is not deal execution — it is dossier integration: inherited IBs, agency history, CMC source documents, safety language, and clinical narratives have to be absorbed without creating long-term fragmentation. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/parabilis-record-ipo-parallel-indication-writing https://asthra-writer.ai/blog/parabilis-record-ipo-parallel-indication-writing Thu, 18 Jun 2026 00:00:00 GMT Parabilis Medicines raised $670M in a record-setting biotech IPO, giving it capital to advance zolucatetide toward Phase 3 in desmoid tumors while moving more aggressively into additional indications. For the writing organisation, that changes the operating model: shared molecule content, synchronised safety language, product-level CMC, and indication-specific clinical narratives now have to move in parallel. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/uniqure-amt-130-reversal-whiplashed-bla-writing-organisation https://asthra-writer.ai/blog/uniqure-amt-130-reversal-whiplashed-bla-writing-organisation Thu, 18 Jun 2026 00:00:00 GMT FDA has reopened an accelerated-approval path for uniQure's AMT-130 gene therapy for Huntington's disease, after previously saying the existing Phase 1/2 data were insufficient and recommending another trial. The BLA now has to present one coherent argument across prior FDA alignment, later FDA skepticism, and renewed FDA openness — while grounding the case in the matured three-year data, external-control logic, and confirmatory-trial plan. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/build-partner-purpose-built-pharma-ai-question https://asthra-writer.ai/blog/build-partner-purpose-built-pharma-ai-question Wed, 10 Jun 2026 00:00:00 GMT Pharma leaders are increasingly asking whether to build AI in-house or partner with vendors. That framing is too narrow. The real question is architectural — does the system constrain sources, surface inference, preserve writer judgment, and produce provenance by default? A purpose-built regulatory-writing platform can be internal, vendor-led, or hybrid. What matters is what the architecture asks the writer to verify after generation. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/gsk-nuvalent-nda-integration-live-pdufa-window https://asthra-writer.ai/blog/gsk-nuvalent-nda-integration-live-pdufa-window Wed, 10 Jun 2026 00:00:00 GMT GSK's $10.6B acquisition of Nuvalent brings two late-stage oncology NDAs already under FDA review: zidesamtinib, with a September 18, 2026 target action date, and neladalkib, with a November 27, 2026 target action date. The strategic logic is lung cancer. The writing problem is continuity — agency history, IR responses, labeling, and launch-facing documents now have to survive an ownership transition inside a live PDUFA window. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/biogen-salanersen-licensed-asset-writing-inheritance-phase-3 https://asthra-writer.ai/blog/biogen-salanersen-licensed-asset-writing-inheritance-phase-3 Mon, 08 Jun 2026 00:00:00 GMT FDA granted Breakthrough Therapy Designation to Biogen's salanersen/BIIB115 for SMA on June 4, 2026. The once-yearly antisense oligonucleotide was discovered by Ionis and licensed to Biogen, which is now running three global Phase 3 studies. The writing-org story is how a licensee turns inherited early-development architecture into a coherent registrational dossier. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/fda-accelerated-approval-confirmatory-trial-underway-writing-surface https://asthra-writer.ai/blog/fda-accelerated-approval-confirmatory-trial-underway-writing-surface Mon, 08 Jun 2026 00:00:00 GMT FDA's draft guidance explains when a confirmatory trial may be considered 'underway' for accelerated approval: a credible target completion date, sponsor progress and plans that provide sufficient assurance of timely completion, and initiated enrollment. For sponsors, the implication is practical — the confirmatory-trial plan now has to be written as a defensible, traceable submission argument. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/lilly-boehringer-module-3-problem-manufacturing-geography-shifts https://asthra-writer.ai/blog/lilly-boehringer-module-3-problem-manufacturing-geography-shifts Mon, 08 Jun 2026 00:00:00 GMT Lilly is reducing its planned Alzey investment by roughly half, and Boehringer Ingelheim has paused or stopped €900M of German infrastructure spend. The trigger is healthcare-cost reform and industrial-policy pressure. The regulatory-writing implication is conditional but important: if manufacturing, testing, release, or supply-chain dependencies change, Module 3 and variation narratives have to move quickly. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/scotus-hikma-amarin-skinny-label-labeling-teams https://asthra-writer.ai/blog/scotus-hikma-amarin-skinny-label-labeling-teams Mon, 08 Jun 2026 00:00:00 GMT On June 4, 2026, the Supreme Court unanimously sided with Hikma in its skinny-label dispute with Amarin. The ruling protects the carved-out-label pathway, but it also sharpens the writing lesson: the label, public statements, medical-information responses, and promotional materials must not create a record of affirmative encouragement for the patented use. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/from-one-line-indication-to-cited-protocol-synopsis https://asthra-writer.ai/blog/from-one-line-indication-to-cited-protocol-synopsis Fri, 05 Jun 2026 00:00:00 GMT Asthra's seed-then-expand authoring flow turns a bare indication into a complete, standards-aligned protocol synopsis — drafted end-to-end, grounded in registered trial evidence, and surfaced as cited decisions the writer can steer. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/what-is-regulatory-writing-automation https://asthra-writer.ai/blog/what-is-regulatory-writing-automation Thu, 04 Jun 2026 00:00:00 GMT Regulatory writing automation is the use of AI to draft, cite, and QC regulated documents like CSRs, PSURs, DSURs, CERs, and CMC modules. Definition, examples, and what to look for in 2026. Fundamentals guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/when-zero-citations-is-the-wrong-alarm https://asthra-writer.ai/blog/when-zero-citations-is-the-wrong-alarm Wed, 03 Jun 2026 00:00:00 GMT Our grounding metric read near-zero on the sections we'd grounded most carefully. We spent a week 'fixing' the drafting before we realized the number was lying — not about the drafts, about itself. The lesson: a confident, wrong metric is worse than no metric. Fundamentals guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/brenus-pharma-stc-1010-ind-acceptance-novel-modality-multi-region-writing https://asthra-writer.ai/blog/brenus-pharma-stc-1010-ind-acceptance-novel-modality-multi-region-writing Mon, 01 Jun 2026 00:00:00 GMT FDA accepted Brenus Pharma's IND for STC-1010 — a first-in-class allogeneic in vivo immunotherapy built on Stimulated Ghost Cells technology — for MSS metastatic colorectal cancer. The program already holds ANSM and AFMPS authorisations in Europe. Multi-region, novel-modality, pre-guidance writing is its own architecture problem. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/bridgebio-bbp-418-priority-review-first-treatment-lgmd-writing-load https://asthra-writer.ai/blog/bridgebio-bbp-418-priority-review-first-treatment-lgmd-writing-load Mon, 01 Jun 2026 00:00:00 GMT BridgeBio's NDA for oral BBP-418 in LGMD2I/R9 was accepted with Priority Review on May 27, 2026 — target action date November 27. If approved, BBP-418 would be the first treatment for any form of limb-girdle muscular dystrophy. The dossier carries four regulatory designations across two agencies. The writing problem is the compression of a full submission program into a six-month review. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/replimune-third-bla-melanoma-when-fda-stands-by-rejection https://asthra-writer.ai/blog/replimune-third-bla-melanoma-when-fda-stands-by-rejection Mon, 01 Jun 2026 00:00:00 GMT Replimune is preparing a third BLA submission for RP1 plus nivolumab in advanced melanoma after two CRLs in 2025 and April 2026. Unlike Outlook's wet AMD program, there is no appeal reversal here — the FDA has maintained its substantial-evidence objection to the IGNYTE trial design across cycles. The third-cycle writing problem is different when the regulatory posture has not changed. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/every-run-every-quality-flag-end-of-run-qc https://asthra-writer.ai/blog/every-run-every-quality-flag-end-of-run-qc Thu, 28 May 2026 00:00:00 GMT When the agent finishes drafting, Asthra runs a structured QC pass — cross-reference integrity, statistical-claim sourcing, citation density, gap detection — and ships a quality_report.json alongside the draft. Here is what it checks and why. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/tables-and-figures-in-the-chat-agent-driven-python-you-can-audit https://asthra-writer.ai/blog/tables-and-figures-in-the-chat-agent-driven-python-you-can-audit Thu, 28 May 2026 00:00:00 GMT Adverse-event line listings, sales-exposure data, lab parameter shifts — the data behind a CSR or PSUR runs into thousands of rows. Asthra's data analysis agent handles the analysis inside the chat with deterministic Python, every step audit-logged. No manual filtering, no LLM-fabricated numbers. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/walk-away-drafting-how-to-generate-a-csr-overnight https://asthra-writer.ai/blog/walk-away-drafting-how-to-generate-a-csr-overnight Thu, 28 May 2026 00:00:00 GMT Initiate the run, step away, and come back to the studio fully briefed. Asthra lands a first draft + bibliography + hyperlinks + QC report in 1–2 hours; the writer reviews and refines in the studio with the full agent history in view — nothing is lost between the run and your review. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/whats-in-a-regulatory-grade-run-bundle https://asthra-writer.ai/blog/whats-in-a-regulatory-grade-run-bundle Thu, 28 May 2026 00:00:00 GMT Every Asthra run ships four artifacts side by side — the .docx, traceability.json, quality_report.json, and run_manifest.json. Each one answers a specific question a regulator or auditor would ask, and together they make the deliverable portable, reproducible, and inspector-ready. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/camizestrant-same-trial-two-verdicts-cross-region-submission-writing https://asthra-writer.ai/blog/camizestrant-same-trial-two-verdicts-cross-region-submission-writing Wed, 27 May 2026 00:00:00 GMT EMA's CHMP recommended approval of AstraZeneca's camizestrant combination after SERENA-6 showed a 56% reduction in risk of progression or death. FDA's ODAC voted 6-3 against a favorable benefit-risk assessment for broadly the same proposed use, focusing on the pre-progression ESR1-triggered switch design. The FDA has now extended its review. The lesson for global submission teams is not that the data changed by region. It is that the regulatory question did. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/lilly-three-vaccine-acquisitions-acquirer-side-writing-inheritance https://asthra-writer.ai/blog/lilly-three-vaccine-acquisitions-acquirer-side-writing-inheritance Wed, 27 May 2026 00:00:00 GMT Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company for up to approximately $3.83 billion. The strategic logic is infectious-disease prevention. The regulatory-writing problem is integration: three vaccine portfolios, three document histories, three sets of agency assumptions, and one acquirer-side writing organisation that has to make them coherent. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/outlook-fourth-shot-writing-playbook-after-three-crls https://asthra-writer.ai/blog/outlook-fourth-shot-writing-playbook-after-three-crls Wed, 27 May 2026 00:00:00 GMT Outlook Therapeutics expects to resubmit LYTENAVA/ONS-5010 for wet AMD in June 2026 after FDA granted its appeal and concluded that substantial evidence of effectiveness has been established. After three CRLs across manufacturing, inspectional, and efficacy issues, the fourth-cycle BLA is a case study in cross-cycle traceability and evidence reframing. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/bms-anthropic-partnership-where-ai-pays-off-in-pharma https://asthra-writer.ai/blog/bms-anthropic-partnership-where-ai-pays-off-in-pharma Mon, 25 May 2026 00:00:00 GMT BMS announced an Anthropic R&D partnership the same week a CRO report said AI keeps repeating the same trial-design mistakes. Both are true. The question isn't whether AI belongs in pharma — it's which layer of the workflow pays off first. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/retatrutide-and-the-multi-indication-writing-org-problem https://asthra-writer.ai/blog/retatrutide-and-the-multi-indication-writing-org-problem Mon, 25 May 2026 00:00:00 GMT Retatrutide's Phase 3 obesity readout is the headline. The operating story is the program shape — one molecule running pivotal trials across obesity, T2D, OSA, MASH, cardiovascular outcomes and knee osteoarthritis, with the GLP class expanding into more indications behind it. That is not a hiring problem. It is a writing-architecture problem. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/from-prompt-engineering-to-standards-engineering https://asthra-writer.ai/blog/from-prompt-engineering-to-standards-engineering Wed, 20 May 2026 00:00:00 GMT The first wave of AI in regulatory writing was the chat box. We built a versioned skill registry instead — and it is becoming the system-of-record for how regulatory standards apply to a draft. Fundamentals guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/hyperlinks-belong-in-the-draft-not-the-publishing-phase https://asthra-writer.ai/blog/hyperlinks-belong-in-the-draft-not-the-publishing-phase Wed, 20 May 2026 00:00:00 GMT Cross-references in regulatory submissions usually get wired up weeks after the draft is locked. We moved that work into the draft itself — anchors at write time, hyperlinks before publishing. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/literature-search-inside-the-regulatory-draft https://asthra-writer.ai/blog/literature-search-inside-the-regulatory-draft Wed, 20 May 2026 00:00:00 GMT PubMed, ClinicalTrials.gov, and bioRxiv are now reachable from inside Asthra's chat — without the browser-tab detour that used to break a writer's flow and let evidence go stale. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/atara-pierre-fabre-third-shot-anatomy-of-a-post-rejection-rewrite https://asthra-writer.ai/blog/atara-pierre-fabre-third-shot-anatomy-of-a-post-rejection-rewrite Mon, 18 May 2026 00:00:00 GMT FDA has indicated a path to reconsider Atara and Pierre Fabre's twice-rejected tabelecleucel BLA. In a third-shot package, the writing function becomes load-bearing: every claim, analysis, and cross-reference has to map back to the prior CRL. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/cder-loses-its-chief-when-the-drug-centers-top-reviewer-walks-mid-cycle https://asthra-writer.ai/blog/cder-loses-its-chief-when-the-drug-centers-top-reviewer-walks-mid-cycle Mon, 18 May 2026 00:00:00 GMT Endpoints reports CDER chief Tracy Beth Høeg is expected to leave the FDA, days after Commissioner Makary's exit. The drug center is now the third top FDA seat in turnover inside two weeks. Sponsors with active CDER submissions need a reviewer-agnostic plan. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/immgolis-golimumab-86th-biosimilar-totality-of-evidence-narrative https://asthra-writer.ai/blog/immgolis-golimumab-86th-biosimilar-totality-of-evidence-narrative Mon, 18 May 2026 00:00:00 GMT FDA approved Immgolis and Immgolis Intri as the first interchangeable biosimilars to Simponi and Simponi Aria in May 2026. For 351(k) writers, the useful lesson is not the approval count. It is the evidence hierarchy FDA highlighted: analytical similarity first, with PK and immunogenicity supporting the totality-of-evidence narrative. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/in-vivo-car-t-at-asgct-2026-the-ind-enabling-writing-problem https://asthra-writer.ai/blog/in-vivo-car-t-at-asgct-2026-the-ind-enabling-writing-problem Mon, 18 May 2026 00:00:00 GMT ASGCT 2026 showed growing momentum around in vivo cell engineering, from in vivo CAR-T to gene writing and gene regulation platforms. The science is advancing quickly, but the IND-enabling writing challenge is still unresolved: how do sponsors build CMC and nonclinical narratives when the precedent base is thin and borrowed from adjacent modalities? Fundamentals guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/zillow-for-abandoned-therapies-what-an-acquirer-inherits-on-regulatory-side https://asthra-writer.ai/blog/zillow-for-abandoned-therapies-what-an-acquirer-inherits-on-regulatory-side Mon, 18 May 2026 00:00:00 GMT ASGCT and the Orphan Therapeutics Accelerator launched CGTxchange in May 2026 to help shelved cell and gene therapy programs find new sponsors. For acquirers, the regulatory file is not just diligence material. It is the operating manual for whether the asset can be restarted without losing agency context. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/cnpv-pilot-at-seven-approvals-bizengri-and-the-priority-voucher-pathway https://asthra-writer.ai/blog/cnpv-pilot-at-seven-approvals-bizengri-and-the-priority-voucher-pathway Thu, 14 May 2026 00:00:00 GMT The FDA's Commissioner's National Priority Voucher pilot just landed its seventh approval with Bizengri for NRG1-fusion cholangiocarcinoma. A June 4 public hearing will shape what comes next. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/fda-drug-repurposing-rfi-why-this-is-a-regulatory-writing-opportunity https://asthra-writer.ai/blog/fda-drug-repurposing-rfi-why-this-is-a-regulatory-writing-opportunity Thu, 14 May 2026 00:00:00 GMT The FDA opened a docket on May 13 asking for drug repurposing candidates — explicitly inviting AI/ML preclinical evidence. Comments are due through June 29. The window matters more than the form. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/from-ipo-to-first-annual-report-the-disclosure-stack-newly-public-biotechs-miss https://asthra-writer.ai/blog/from-ipo-to-first-annual-report-the-disclosure-stack-newly-public-biotechs-miss Thu, 14 May 2026 00:00:00 GMT An IPO doubles a biotech's disclosure workload overnight. The regulatory writing function rarely gets re-resourced in time. Here is what gets missed and how to plan against it. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/makary-out-what-an-interim-fda-leadership-window-means-for-your-active-submission https://asthra-writer.ai/blog/makary-out-what-an-interim-fda-leadership-window-means-for-your-active-submission Thu, 14 May 2026 00:00:00 GMT FDA Commissioner Marty Makary resigned May 12, 2026. Existing guidance stays operative; new guidance pauses. Every sponsor with a submission in flight should re-plan inside 90 days. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/milestone-payments-as-a-writing-pace-forcing-function https://asthra-writer.ai/blog/milestone-payments-as-a-writing-pace-forcing-function Thu, 14 May 2026 00:00:00 GMT When a partnership milestone pays, the regulatory writing function inherits a calendar. The partnership announcement is the loud event. The document acceleration that follows is the quiet one. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/the-five-billion-dollar-impairment-and-the-documentation-lifecycle https://asthra-writer.ai/blog/the-five-billion-dollar-impairment-and-the-documentation-lifecycle Thu, 14 May 2026 00:00:00 GMT When a commercial decision retroactively reshapes a product's value, the documentation stack does not auto-adjust. The CSL impairment this week is a case study in why regulatory writing needs to be in the room before the writedown. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/biotech-newco-chinese-assets-and-the-ind-bridging-problem https://asthra-writer.ai/blog/biotech-newco-chinese-assets-and-the-ind-bridging-problem Mon, 11 May 2026 00:00:00 GMT Endpoints identified 18 US biotechs since 2025 launching with in-licensed Chinese clinical-stage assets. The startup model is new. The regulatory writing problem — bridging Chinese trial documentation into a US IND — is not. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/cnpv-pilot-seven-approvals-what-the-voucher-program-tells-writers https://asthra-writer.ai/blog/cnpv-pilot-seven-approvals-what-the-voucher-program-tells-writers Mon, 11 May 2026 00:00:00 GMT Bizengri's NRG1-cholangiocarcinoma approval on May 8 marks the seventh FDA approval under the Commissioner's National Priority Voucher pilot. The pace is the signal. Here's what to read into it before the June 4 public hearing. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/daiichi-sankyo-950m-adc-writedown-decommissioning-the-capex-bet https://asthra-writer.ai/blog/daiichi-sankyo-950m-adc-writedown-decommissioning-the-capex-bet Mon, 11 May 2026 00:00:00 GMT Daiichi recorded a ¥149.4B 'extraordinary loss' on May 8 after scrapping antibody-drug-conjugate manufacturing capacity. The decommissioning problem returns — this time at the capex level, with documentation implications that follow. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/postapproval-pregnancy-safety-final-guidance-and-the-psur-architecture-problem https://asthra-writer.ai/blog/postapproval-pregnancy-safety-final-guidance-and-the-psur-architecture-problem Mon, 11 May 2026 00:00:00 GMT FDA's May 8 final guidance on postapproval pregnancy safety studies adds new methodological expectations for pregnancy registries, RWD complements, and case-report studies. The labelling implications land squarely in the PSUR. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/cber-leadership-vacuum-what-it-means-for-cell-and-gene-therapy-submissions https://asthra-writer.ai/blog/cber-leadership-vacuum-what-it-means-for-cell-and-gene-therapy-submissions Thu, 07 May 2026 00:00:00 GMT Endpoints reports the FDA has narrowed its search for a CBER leader without a name attached. Sponsors with active cell and gene therapy filings need a tactical read on what shifts during interim leadership periods. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/decommissioning-a-program-stack-when-the-sponsor-terminates-the-program https://asthra-writer.ai/blog/decommissioning-a-program-stack-when-the-sponsor-terminates-the-program Thu, 07 May 2026 00:00:00 GMT Pfizer ending its Trillium-related programs is the headline. The regulatory writing question is what happens to the documentation, the audit trail, and the institutional memory when a sponsor closes a program down — especially mid-stream. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/fda-elsa-4-0-and-halo-when-the-reviewer-has-ai-editing-alone-falls-behind https://asthra-writer.ai/blog/fda-elsa-4-0-and-halo-when-the-reviewer-has-ai-editing-alone-falls-behind Thu, 07 May 2026 00:00:00 GMT FDA just shipped Elsa 4.0 with custom agents, document generation, OCR, and secure search — and consolidated 40+ submission portals into HALO. The asymmetry between the reviewer's stack and the writer's stack just widened. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/fda-one-day-inspectional-assessments-continuous-readiness-replaces-cycle-prep https://asthra-writer.ai/blog/fda-one-day-inspectional-assessments-continuous-readiness-replaces-cycle-prep Thu, 07 May 2026 00:00:00 GMT The FDA's new one-day pilot ran 46 inspections in two months and is expanding through FY26. The era of preparing for inspection windows is ending — your documentation has to hold up cold. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/ond-custom-4-1-fda-internal-review-tooling-versions-faster-than-most-pipelines https://asthra-writer.ai/blog/ond-custom-4-1-fda-internal-review-tooling-versions-faster-than-most-pipelines Thu, 07 May 2026 00:00:00 GMT The Office of New Drugs released version 4.1 of its custom review tooling on May 4, 2026. Two meaningful versions inside a year is the leading indicator. Here's how to read it. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/orphan-drug-designation-and-the-six-month-csr-calendar-reset https://asthra-writer.ai/blog/orphan-drug-designation-and-the-six-month-csr-calendar-reset Thu, 07 May 2026 00:00:00 GMT Orphan Drug Designation is celebrated as good news. For the regulatory writing function, it is a calendar event that compresses CSR, briefing book, and pre-BLA preparation into a much tighter window than most teams plan for. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/pdufa-viii-reading-the-fy27-dear-colleague-letter-as-a-submission-forecast https://asthra-writer.ai/blog/pdufa-viii-reading-the-fy27-dear-colleague-letter-as-a-submission-forecast Thu, 07 May 2026 00:00:00 GMT The FY27 PDUFA Dear Colleague Letter dropped on May 4. Most teams skim it for fee schedules. The strategic teams read it for what it implies about review capacity and submission throughput in 2027. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/phase-2-win-plus-capital-raise-equals-six-months-of-documentation-crunch https://asthra-writer.ai/blog/phase-2-win-plus-capital-raise-equals-six-months-of-documentation-crunch Thu, 07 May 2026 00:00:00 GMT A positive Phase 2 readout followed by a financing round looks like a celebration. For the regulatory writing function, it's the start of a 180-day timeline collision that most teams underestimate. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/project-optimus-and-the-orr-bridge-when-confirmatory-readouts-have-to-carry https://asthra-writer.ai/blog/project-optimus-and-the-orr-bridge-when-confirmatory-readouts-have-to-carry Thu, 07 May 2026 00:00:00 GMT Post-Project Optimus, the FDA's tolerance for narrow ORR-based accelerated approvals has tightened. The CSR and BLA narrative for a confirmatory readout now has to do framing work the primary readout used to do alone. Use Cases guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/beyond-frontier-models-teaser https://asthra-writer.ai/blog/beyond-frontier-models-teaser Tue, 05 May 2026 00:00:00 GMT Frontier LLMs and generic RAG aren't enough for regulatory writing. A purpose-built stack — document model, retrieval, planning, and verification — is what separates a demo from a draft a regulator will accept. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/why-regulatory-writing-is-broken-teaser https://asthra-writer.ai/blog/why-regulatory-writing-is-broken-teaser Tue, 05 May 2026 00:00:00 GMT Regulatory writing teams spend 60–70% of project time on mechanical document assembly while sponsors lose $1.4M per day of delay. Here's why generic AI tools fall short, and what an agentic, document-aware system actually changes. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/first-protac-approval-rewrites-the-regulatory-playbook-for-degraders https://asthra-writer.ai/blog/first-protac-approval-rewrites-the-regulatory-playbook-for-degraders Sat, 02 May 2026 00:00:00 GMT FDA's approval of vepdegestrant establishes the first regulatory precedent for PROTAC protein degraders, creating a framework that will shape development strategies across the emerging degrader landscape. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/fda-s-first-non-antipsychotic-dementia-agitation-approval-changes-treatment-para https://asthra-writer.ai/blog/fda-s-first-non-antipsychotic-dementia-agitation-approval-changes-treatment-para Fri, 01 May 2026 00:00:00 GMT FDA approves Auvelity for Alzheimer's agitation, marking a breakthrough in dementia care. We analyze the regulatory pathway, novel endpoints, and what this means for CNS drug development. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/kymera-s-kt-621-fast-track-what-degrader-designations-signal-for-respiratory-pro https://asthra-writer.ai/blog/kymera-s-kt-621-fast-track-what-degrader-designations-signal-for-respiratory-pro Fri, 01 May 2026 00:00:00 GMT FDA grants Fast Track to Kymera's IRAK4 degrader KT-621 for eosinophilic asthma. We analyze what this designation reveals about regulatory pathways for targeted protein degradation in respiratory disease. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/when-partnerships-end-documentation-inheritance-becomes-a-regulatory-burden https://asthra-writer.ai/blog/when-partnerships-end-documentation-inheritance-becomes-a-regulatory-burden Fri, 01 May 2026 00:00:00 GMT Big pharma partnership terminations leave smaller biotechs holding jointly-authored documents that need sponsor re-issue. The regulatory writing burden of these terminations is rarely discussed but significant. Industry Analysis guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/writer-defined-provenance-in-ai-regulatory-writing https://asthra-writer.ai/blog/writer-defined-provenance-in-ai-regulatory-writing Tue, 15 Jul 2025 00:00:00 GMT How writer-defined provenance ensures that every piece of AI-generated regulatory content is traceable to its specific source document, section, table, or image. Technology guru@asthra-writer.ai (Asthra AI Team) https://asthra-writer.ai/blog/csr-timelines-from-one-month-to-less-than-ten-days https://asthra-writer.ai/blog/csr-timelines-from-one-month-to-less-than-ten-days Sun, 15 Jun 2025 00:00:00 GMT How AI-assisted drafting is compressing Clinical Study Report timelines from weeks of manual effort to days of focused writing, without compromising quality or traceability. Use Cases guru@asthra-writer.ai (Asthra AI Team)